Hidaka Hiedo, Seki Naohiko, Yoshino Hirofumi, Yamasaki Takeshi, Yamada Yasutoshi, Nohata Nijiro, Fuse Miki, Nakagawa Masayuki, Enokida Hideki
Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Oncotarget. 2012 Jan;3(1):44-57. doi: 10.18632/oncotarget.417.
MicroRNAs (miRNA) are non-coding RNAs, approximately 22 nucleotides in length, which function as post-transcriptional regulators. A large body of evidence indicates that miRNAs regulate the expression of cancer-related genes involved in proliferation, migration, invasion, and metastasis. The aim of this study was to identify novel cancer networks in renal cell carcinoma (RCC) based on miRNA expression signatures obtained from RCC clinical specimens. Expression signatures revealed that 103 miRNAs were significantly downregulated (more than 0.5-fold change) in RCC specimens. Functional screening (cell proliferation assays) was performed to identify tumor suppressive activities of 20 downregulated miRNAs. Restoration of mature miRNAs in cancer cells showed that 14 miRNAs (miR-1285, miR-206, miR-1, miR-135a, miR-429, miR-200c, miR-1291, miR-133b, miR-508-3p, miR-360-3p, miR-509-5p, miR-218, miR-335, miR-1255b and miR-1285) markedly inhibited cancer cell proliferation, suggesting that these miRNAs were candidate tumor suppressive miRNAs in RCC. We focused on miR-1285 because it significantly inhibited cancer cell proliferation, invasion, and migration following its transfection. We addressed miR-1285-regulated cancer networks by using genome-wide gene expression analysis and bioinformatics. The data showed that transglutaminase 2 (TGM2) was directly regulated by miR-1285. Silencing of the target gene demonstrated significant inhibition of cell proliferation and invasion in the RCC cells. Furthermore, immunohistochemistry showed that TGM2 expression levels in RCC specimens were significantly higher than those in normal renal tissues. Downregulation of tumor suppressive miR-1285, which targets oncogenic genes including TGM2, might contribute to RCC development. Thus, miR-1285 modulates a novel molecular target and provides new insights into potential mechanisms of RCC oncogenesis.
微小RNA(miRNA)是长度约为22个核苷酸的非编码RNA,其作为转录后调节因子发挥作用。大量证据表明,miRNA调节参与增殖、迁移、侵袭和转移的癌症相关基因的表达。本研究的目的是基于从肾细胞癌(RCC)临床标本中获得的miRNA表达特征,识别RCC中的新型癌症网络。表达特征显示,103种miRNA在RCC标本中显著下调(变化超过0.5倍)。进行功能筛选(细胞增殖测定)以鉴定20种下调的miRNA的肿瘤抑制活性。在癌细胞中恢复成熟miRNA表明,14种miRNA(miR-1285、miR-206、miR-1、miR-135a、miR-429、miR-200c、miR-1291、miR-133b、miR-508-3p、miR-360-3p、miR-509-5p、miR-218、miR-335、miR-1255b和miR-1285)显著抑制癌细胞增殖,表明这些miRNA是RCC中候选的肿瘤抑制性miRNA。我们重点研究了miR-1285,因为其转染后显著抑制癌细胞增殖、侵袭和迁移。我们通过全基因组基因表达分析和生物信息学研究了miR-1285调控的癌症网络。数据显示,转谷氨酰胺酶2(TGM2)受miR-1285直接调控。靶基因沉默显示对RCC细胞的增殖和侵袭有显著抑制作用。此外,免疫组织化学显示,RCC标本中TGM2表达水平显著高于正常肾组织。靶向包括TGM2在内的致癌基因的肿瘤抑制性miR-1285下调可能有助于RCC的发生发展。因此,miR-1285调节一种新的分子靶点,并为RCC肿瘤发生的潜在机制提供了新的见解。